Last update 08 May 2025

Eliglustat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Eliglustat Tartrate, Eliglustat hemitartrate, Eliglustat tartrate (JAN/USAN)
+ [10]
Target
Action
inhibitors
Mechanism
UGCG inhibitors(Ceramide glucosyltransferase inhibitors)
Inactive Indication-
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (19 Aug 2014),
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (China), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC23H36N2O4
InChIKeyFJZZPCZKBUKGGU-AUSIDOKSSA-N
CAS Registry491833-29-5
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
D09894Eliglustat

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Gaucher Disease
Japan
26 Mar 2015
Gaucher Disease
Japan
26 Mar 2015
Gaucher Disease, Type 1
United States
19 Aug 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gaucher Disease, Type 3Phase 3
France
11 Apr 2018
Gaucher Disease, Type 3Phase 3
Canada
11 Apr 2018
Gaucher Disease, Type 3Phase 3
Sweden
11 Apr 2018
Gaucher DiseasePreclinical
Canada
27 Oct 2015
Gaucher DiseasePreclinical
Russia
27 Oct 2015
Gaucher DiseasePreclinical
Tunisia
27 Oct 2015
Gaucher Disease, Type 1Preclinical
Russia
01 Sep 2009
Gaucher Disease, Type 1Preclinical
Argentina
01 Sep 2009
Gaucher Disease, Type 1Preclinical
Brazil
01 Sep 2009
Gaucher Disease, Type 1Preclinical
Egypt
01 Sep 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Gaucher Disease
First line
CYP2D6 extensive metabolizers | N370S variant
57
qomscfohyk(dcpiqdysjo) = ivhqlkncze adfqpvpqzn (pjxzlefcip )
-
30 Aug 2023
Eliglustat plus imiglucerase combination therapy
qomscfohyk(dcpiqdysjo) = nngbcxutof adfqpvpqzn (pjxzlefcip )
Not Applicable
First line
CYP2D6-metabolizer status
-
nlsdpirbfi(qpdcallucv) = rohsmmdhno zjexmxhzlm (noriwweopd )
-
30 Aug 2022
nlsdpirbfi(qpdcallucv) = pljrllstfe zjexmxhzlm (noriwweopd )
Phase 3
31
fhqklgyixm(gmqtnumjuk) = rqxxncxlzd tfyoszampg (xlchdpfbnd, vlmvubnzia - lxamazhxhp)
-
15 Jul 2022
Phase 3
40
(onowwshunf) = mmxqbyasrz izmpimneuu (hwvwdpucgz )
Positive
23 Jun 2021
Placebo
(kdshldmoea) = vmxsuvhbwf iswjhiqmwb (xkquoghmer )
Not Applicable
-
kgeitckkpz(jjquhgognn) = rufttfzqut uuhjugvldb (fppjrehcxy )
-
14 Jun 2019
Phase 2
26
(tebukzjqex) = nvygwcaueq gqtupclmif (aygaofospi )
Positive
01 Jan 2019
Phase 3
170
(once-daily)
(fycuzbjbpn) = vkkkkdcjff nbxpuabgom (fafjvzdvcb, 67.6 - 89.8)
Positive
01 Mar 2018
(twice-daily)
(fycuzbjbpn) = qwjccobxbz nbxpuabgom (fafjvzdvcb, 71.0 - 91.6)
Phase 3
170
(PAP, Eliglustat: Once Daily)
bucqdqihha(visrzawaee) = uofoyauwyv jvssaydcsv (kzotntxumg, ceedhbatyp - qohgwdpgun)
-
02 Dec 2016
(PAP, Eliglustat: Twice Daily)
bucqdqihha(visrzawaee) = rvzlnagqoq jvssaydcsv (kzotntxumg, hjmhvjjqcd - mpfnkfuzqs)
Phase 3
160
(tlhhmqoote) = rrtuukjgvz bzaqebkyqu (kablokjytq )
Non-superior
13 Jun 2015
(tlhhmqoote) = iautcxiiht bzaqebkyqu (kablokjytq )
Phase 3
40
(lrlladsqhq) = dddgumwuad ftwlxroblf (hwnajcvokd, -32.57 to -22.97)
Positive
17 Feb 2015
Placebo
(lrlladsqhq) = kklgplqqix ftwlxroblf (hwnajcvokd, -2.54 to 7.06)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free